14.10.2009

The US Federal Trade Commission has cleared the way for Pfizer's $68 billion acquisition of Wyeth, saying it was satisfied with the previously disclosed divestitures involving animal health products. Pfizer has also won approval from Canadian antitrust authorities for the deal. The merger, which was announced in January, received approval from the European Commission in July.
Government approval is conditional on the divestiture of animal health assets. The government found the companies’ human health products were complimentary and would pose no competitive impact to the prescription drug market.